MOUNTAIN VIEW, Calif, November, 2015 — Based on its recent analysis of the European clinical laboratory services market, Frost & Sullivan recognizes Euro Diagnostica with the 2015 European Frost & Sullivan Award for Customer Value Leadership. Within a short span of time and following its merger with Biomonitor in July 2014, Euro Diagnostica has established itself as a proficient and reliable partner to customers in the field of theranostics and personalized medicine by offering customized assay and service solutions. Offerings can also involve immunological diagnostic tools (IVD) for specific parameters as well as functional cell based reporter gene assays.
“Owing to its flexibility as a complete, cross-functional organization, Euro Diagnostica is an optimal ally to have throughout the drug development process, beginning from the exploratory phase to the clinical trial stage and beyond,” said Frost & Sullivan Vice President, Nitin Naik. “Its in-house lab, Wieslab, is also at the forefront of providing bioanalytical services according to applicable guidelines and regulatory requirements".
The company’s iLite™ technology is an ideal example of recent innovation. Patients with the same disease can respond differently to drug substances, such as biologicals; iLite™ provides physicians with information that will facilitate the customization of treatment regimens for each individual.
Euro Diagnostica is able to deliver such wide-ranging, tailored solutions due to its cross-functional and highly skilled team. Moreover, the company believes that fostering long-term personal relationships with current and new customers to understand their requirements is a prerequisite for successful commercial results.
“Through excellent customer relations and consistent technical support, Euro Diagnostica has strengthened its growth potential in the theranostics services space,” noted Mr.Naik. “Combining the strengths of the versatile iLite™ platform with twenty years of rich experience in customized development, validation and production processes has made Euro Diagnostica a favorite firm to partner for the European market.” Euro Diagnostica is thus an optimal assay partner in all phases of drug development, from exploratory phase to and beyond clinical trials.
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on increasing the return on the investment that customers make in its services or products. The award recognizes the company's inordinate focus on enhancing the value that its customers receive, beyond simply good customer service, leading to improved customer retention and, ultimately, customer base expansion.
Frost & Sullivan’s Best Practices Awards recognize companies in a variety of regional and global markets for outstanding achievement in areas such as leadership, technological innovation, customer service and product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research.
About Euro Diagnostica
Euro Diagnostica’s goal is to constantly develop solutions to aid clinicians in diagnosis, prognosis, monitoring and treatment of autoimmune and related diseases. In July 2014, Euro Diagnostica entered into a merger agreement with Biomonitor, a leading company in theranostics and personalized medicine. Today, together with Biomonitor, Euro Diagnostica is providing a large portfolio of kits, laboratory and OEM/custom manufacturing services, as well as drug monitoring and customized assay development for measurement of biological activity in various biological and biosimilar drugs.
Else Beth Trautner
P: +46 (40) 53 76 85
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies? Contact us: Start the discussion.
P: 210. 247.3870
F: 210.348.1003« Back